RFC1 expansions are a common cause of idiopathic sensory neuropathy by Curr\uf2, Riccardo et al.
ORIGINAL ARTICLE
RFC1 expansions are a common cause of
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After extensive evaluation, one-third of patients affected by polyneuropathy remain undiagnosed and are labelled as having chronic
idiopathic axonal polyneuropathy, which refers to a sensory or sensory-motor, axonal, slowly progressive neuropathy of unknown
origin. Since a sensory neuropathy/neuronopathy is identified in all patients with genetically confirmed RFC1 cerebellar ataxia,
neuropathy, vestibular areflexia syndrome, we speculated that RFC1 expansions could underlie a fraction of idiopathic sensory
neuropathies also diagnosed as chronic idiopathic axonal polyneuropathy.
We retrospectively identified 225 patients diagnosed with chronic idiopathic axonal polyneuropathy (125 sensory neuropathy, 100
sensory-motor neuropathy) from our general neuropathy clinics in Italy and the UK. All patients underwent full neurological evalu-
ation and a blood sample was collected for RFC1 testing.
Biallelic RFC1 expansions were identified in 43 patients (34%) with sensory neuropathy and in none with sensory-motor neur-
opathy. Forty-two per cent of RFC1-positive patients had isolated sensory neuropathy or sensory neuropathy with chronic cough,
while vestibular and/or cerebellar involvement, often subclinical, were identified at examination in 58%. Although the sensory gan-
glia are the primary pathological target of the disease, the sensory impairment was typically worse distally and symmetric, while
gait and limb ataxia were absent in two-thirds of the cases. Sensory amplitudes were either globally absent (26%) or reduced in a
length-dependent (30%) or non-length dependent pattern (44%). A quarter of RFC1-positive patients had previously received an
alternative diagnosis, including Sjögren’s syndrome, sensory chronic inflammatory demyelinating polyneuropathy and paraneoplas-
tic neuropathy, while three cases had been treated with immune therapies.
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Introduction
Polyneuropathy is a common health problem leading to
neurological consultation, with an estimated prevalence of
1–2.4% in the general population and up to 7% in people
aged 465 years.1,2
Even after extensive evaluation, 25–32% of patients re-
main undiagnosed and are often labelled as having chronic
idiopathic axonal polyneuropathy (CIAP).3–6 CIAP refers to
a sensory or sensory-motor, axonal, slowly progressive neur-
opathy.7 Clinically, the disease burden falls predominantly
or exclusively on the sensory fibres, especially at disease
onset.8 The slow progression of CIAP with an accumulating
burden of disability9 has raised the hypothesis of an
underlying genetic cause.10 However, family history in CIAP
is usually negative and age at onset is significantly higher
than in most known inherited neuropathies.9,11 Previous
attempts at identifying a genetic cause of CIAP were
unsuccessful.12,13
Recently, biallelic intronic AAGGG repeat expansions
in the replication factor complex subunit 1 (RFC1) gene
were identified as the cause of cerebellar ataxia, neur-
opathy, vestibular areflexia syndrome (CANVAS) and a
frequent cause of late onset ataxia.14,15 Notably, a sen-
sory neuropathy/neuronopathy has been present in all the
patients with biallelic RFC1 expansions to date and can
be observed as an isolated complaint in some, possibly
reflecting an early stage of this complex neurological
disease.16
Therefore, we speculated that biallelic RFC1 expansions
could account for a proportion of idiopathic sensory neuro-
pathies also diagnosed as CIAP.
Materials and methods
Patient selection and clinical
evaluation
Patients affected by CIAP were identified through the interroga-
tion of clinical and neurophysiological databases from 2010 to
2019 in general peripheral nerve clinics in multiple centres in
Italy and the UK. Patients were classified as having a sensory-
motor or sensory neuropathy. Importantly, as sporadic CIAP is
the focus of the study, patients previously diagnosed with
CANVAS or with a family history of CANVAS were not
included. The following laboratory investigations were per-
formed in all cases: fasting blood glucose, glycosylated haemo-
globin, folate, vitamin B12 and serum protein immunofixation
electrophoresis.12 Depending on the clinical features, additional
tests were performed, including those for markers of systemic
autoimmunity (antinuclear antibodies, extractable nuclear anti-
gens and antineutrophil cytoplasmic antibodies), paraneoplastic
disorders (onconeural antibodies), HIV, hepatitis B and C infec-
tion, dosage of vitamin E, genetic testing for familial amyloid
polyneuropathy and/or hereditary sensory neuropathies, fat pad
aspiration for amyloid staining, imaging and nerve biopsy. A
detailed algorithm for case enrolment is provided in Fig. 1.
Patients with sensory neuropathy (n = 650) were assessed be-
tween 2010 and 2019 in two Italian University Hospitals (Pavia
and Padova). Of these, 220 could not be contacted or had insuf-
ficient clinical information and were therefore excluded. Fifty-
five per cent of 430 patients (n = 238) were identified as having
another cause of their sensory neuropathy, including diabetes
(n = 78), paraneoplastic syndrome (n = 57), B12 and/or folate
deficiency (n = 47), neuropathy associated with systemic or
rheumatological disease (n = 37), genetic (n = 25), acquired or
familial amyloidosis (n = 6) or hepatitis C, hepatitis B or HIV
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infection (n = 28) and were therefore excluded. We identified 192
patients with idiopathic sensory neuropathy and 62 agreed to
take part in the study. These patients were clinically reassessed,
and a DNA sample was obtained for RFC1 testing. A further
163 patients with a diagnosis of CIAP were identified in general
peripheral nerve clinics in Italy (Genova and Napoli) or the UK
(London and Sheffield), including 63 patients with sensory neur-
opathy and 100 with sensory-motor neuropathy. Overall, 100
patients with sensory-motor and 125 with sensory CIAP were
included in the study and tested for biallelic RFC1 expansions.
RFC1 testing
The presence of RFC1 expansions was assessed as previously
described.14 Briefly, DNA was tested by flanking PCR and re-
peat-primed PCR for AAGGG repeat expansions in RFC1.
Samples without amplifiable products on flanking PCR and a
positive repeat-primed PCR for the AAGGG repeat were tested
by Southern blotting in order to confirm the presence and meas-
ure the size of the biallelic RFC1 expansions. Non-pathogenic
AAAAG or AAAGG expansions were excluded by repeat-
primed PCR in all the cases with positive repeat-primed PCR
for AAGGG expansion.
Ethics
The study was approved by the ethics committee of IRCCS
Fondazione Policlinico San Matteo (p-20170028026) and by
local institutional review boards. All patients gave informed
consent prior to their inclusion in the study. The study complied
with all relevant ethical regulations.
Statistical analysis
Continuous data were expressed as medians (minimum-max-
imum). Statistical differences between subgroups of patients
positive versus negative for RFC1 expansions were tested using
the Mann-Whitney test for quantitative data and Pearson’s chi-
squared test for categorical data. All analyses were performed
using STATA statistical software, version 14.
Data availability
Anonymized data from this study will be shared by request
from any qualified investigator.
Results
Genetic testing
Of 125 patients with sensory neuropathy 43 (34%) carried
biallelic AAGGG repeat expansions in RFC1. Conversely,
none of 100 axonal sensory-motor neuropathies had biallelic
AAGGG expansions.
In RFC1-positive cases, the expansions size, as measured
by Southern blotting, ranged from 249 to 2386 repeat units,
with a median size of 661 repeats for the smaller allele and
810 for the larger allele (Supplementary Fig. 1).
Clinical features of RFC1-positive
patients
Symptoms
The demographic data and clinical features are detailed in
Table 1. The median age at disease onset was 56 years
(range: 30–75). Twenty-five patients were male and 18 were
female. The family history for neuropathy was unremarkable
Figure 1 Flow chart for enrolment of patients with sensory and sensory-motor CIAP. ENMG = electroneuromyography; HSN =
hereditary sensory neuropathy; PN = polyneuropathy.
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in all cases apart from a patient with a sibling who had a
diagnosis of sensory neuropathy.
At onset, 98% of patients (n = 42) had symptoms of sen-
sory neuropathy, including distal numbness (n = 21), tingling
or pins and needles sensation (n = 14), unsteadiness (n = 19)
and pain (n = 10). The distribution of sensory involvement
was length-dependent in 69% of cases (n = 20/29).
Symptoms of dysautonomia (e.g. orthostatic hypotension,
erectile dysfunction or altered sweating) were infrequent at
onset (n = 2). Only two patients reported symptoms suggest-
ive of cerebellar (e.g. slurred speech or difficulties in swal-
lowing) or vestibular dysfunction (e.g. oscillopsia) at disease
onset. When specifically asked, 70% of patients (n = 26/37)
reported a chronic, paroxysmal dry cough, which was often
previously attributed to asthma or gastro-esophageal reflux.
In an asymptomatic 41-year-old male, the sensory neur-
opathy was suspected because of reduced or absent reflexes
tested during a routine medical visit for workplace health
surveillance.
Previous diagnoses
In 26% (n = 11) of genetically confirmed patients, the neur-
opathy was previously attributed to a different cause, includ-
ing inflammatory (n = 7; one vasculitis, three CIDP, one
Sjögren’s syndrome, one post-infectious, one paraneoplastic),
metabolic (n = 3, B12 deficiency) or toxic (n = 1, previous
exposure to hexavalent chromium). Three patients received
immunosuppressive therapy (i.e. steroids, intravenous immu-
noglobulins or mycophenolate) and three had B12 replace-
ment therapy.
Patients were followed up for 4.7 years (range 0–16.7
years). Notably, at the most recent examination, 70% of
patients (n = 30) still had symptoms of isolated neuropathy
and did not report any vestibular or cerebellar complaint.
Disability
The disease was slowly progressive in 81% of cases (n = 35)
and stable in 19% (n = 8). Thirty-seven per cent of patients
(n = 16) lost independent walking: 10 required unilateral
support, five bilateral support and one was wheelchair-
dependent.
Neurological examination
The data from the neurological examinations are summar-
ized in Fig. 2. The median disease duration at the most re-
cent examination was 9.6 years (range: 0.6–31.7 years). Gait
was ataxic in 37% of patients (n = 16), but difficulty in tan-
dem walking was observed in 74% (n = 32). Romberg was
positive in 51% (n = 22), supporting the presence of a prom-
inent peripheral component of the unsteadiness. Eighty-six
per cent of patients (n = 37) had an abnormal sensory exam-
ination. Pinprick and vibratory sensation were impaired in
65% (n = 28) and 81% (n = 35) of patients, respectively.
Conversely, joint position was impaired only in 23% of
cases (n = 10; Fig. 3). Sensory impairment was length-de-
pendent (namely, lower limbs were more affected than upper
limbs and distal limb segments were more affected than
proximal) in 92% (n = 34/37) and symmetric in 95%
(n = 35/37). Nineteen per cent (n = 8) of patients showed in-
coordination during cerebellar testing, but the upper limbs
were involved only in half of them. Strength, tone and plan-
tar reflexes were normal in all patients. Reflexes were usual-
ly decreased or absent, but normal or brisk reflexes were
observed in more than one-third of cases (n = 11 and 5,
respectively).
Abnormalities of eye movements were identified in 50%
of cases, as revealed by the presence of nystagmus (n = 19/
40) or broken pursuit (n = 9/34). Of 26 patients tested, 46%
(n = 12) had an altered bedside head-impulse test.
Nerve conduction studies
The detailed nerve conduction study results are reported in
Table 2. The median delay from symptom onset to the first
nerve conduction study was 5 years (range 0–31 years).
Axonal loss of sensory fibres was generally severe, with glo-
bally absent sensory action potentials in 26% of cases
(n = 11), reduced in a length-dependent pattern (namely, a
greater impairment in the lower than in the upper limbs) in
30% of patients (n = 13) and reduced in a non-length de-
pendent pattern in 44% (n = 19). Sensory conduction
velocities were normal or slightly decreased, consistently
with a loss of fast-conducting large fibres, in all cases (me-
dian value of sural conduction velocity = 41.8 m/s, range:
31.4–51 m/s). We observed a clinical-electrodiagnostic
dissociation with reduction in sensory amplitudes being
worse than expected based on clinical findings in 44%
(n = 19) of cases: six patients with a normal sensory exam-
ination showed diffusely reduced sensory action poten-
tials, with absent sensory action potentials throughout in
two cases; 13 patients with reduced sensation restricted to
Table 1 Clinical features of RFC1 + patients at disease
onset and at most recent evaluation
Demographics n = 43
Males 25 (58%)
Positive family history 1 (2%)
Age at onset 56 (30–75)
Age at examination 67 (41–86)
Symptoms Disease onset Most recent evaluation
Numbness 21 (49%) 27 (63%)
Unsteadiness 19 (44%) 30 (70%)
Tingling/pins and needles 14 (33%) 20 (46%)
Pain 10 (23%) 17 (39%)
Distribution
Length dependent NA 20/29 (69%)
Non-length-dependent NA 9/29 (31%)
Dysautonomia 2 (5%) 9 (21%)
Dysarthria/dysphagia 1 (2%) 10 (23%)
Oscillopsia 1 (2%) 4 (9%)
Chronic cough NA 26/37 (70%)
NA = not available.
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Figure 2 Detailed neurological examination of RFC1 + patients. HIT = head-impulse test; LL = lower limbs; UL = upper limbs; vVOR
= visually-enhanced vestibulo-ocular reflex.
Figure 3 Graphic representation of the distribution of abnormalities at sensory examination. The different shades of colour cor-
respond to different percentages of patients with reduced sensation in the specific area.
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distal segments of the lower limbs had reduced or absent
sensory action potentials in the upper limbs in 38%
(n = 5) and 62% (n = 8), respectively.
Motor nerve conduction studies were normal in all but
two patients with decreased compound muscle action poten-
tials in the lower limbs.
Additional investigations
Cerebellar atrophy was identified in 26% of patients who
underwent brain MRI (n = 7/27). Clinical examination
was more sensitive in detecting cerebellar abnormalities
than brain MRI: only 5 of 20 subjects with clinical evi-
dence of cerebellar dysfunction at examination had defin-
ite cerebellar atrophy on brain MRI. Conversely,
subclinical cerebellar atrophy was identified in only two
cases without cerebellar symptoms or signs at clinical
examination.
Six patients with an abnormal bedside head-impulse
test underwent vestibular testing, which confirmed a
bilateral vestibular areflexia in all of them. CSF analysis
was performed in 13 patients to rule out an
inflammatory cause of the neuropathy and was normal in
all. Four patients underwent a sural nerve biopsy,
showing in all cases a diffuse and severe reduction of myelin-
ated fibre density with no signs of regeneration
(Supplementary Fig. 2).
RFC1 spectrum disorder: clinical
syndrome
Based on history, neurological examination and ancillary
investigations, after 10 years of disease duration, the clinic-
al syndrome could be classified as isolated sensory neur-
opathy in 42% of patients (n = 18), including 19% of cases
with sensory neuropathy and cough (n = 8), in 5% (n = 2)
sensory neuropathy with vestibular areflexia, in 25%
(n = 11) sensory neuropathy with cerebellar dysfunction and
in 28% (n = 12) full CANVAS (Fig. 4).
Predictors of positive RFC1 testing
in patients with sensory neuropathy
To identify the symptoms and signs predictive of positive
RFC1 testing, we compared 43 cases with sensory neur-
opathy and biallelic AAGGG expansions with 58 cases
also diagnosed with sensory neuropathy but negative for
AAGGG repeat expansions (Table 3). The presence of
cough, dysarthria and/or dysphagia, history of falls, clinic-
al evidence of cerebellar or vestibular dysfunction at
examination, reduced vibratory sensation above the knee
in the lower limbs and a progressive course were more
frequently observed in cases carrying biallelic RFC1
expansions. Conversely, the two groups did not signifi-
cantly differ in gender, age of onset, family history, report
Table 2 Details of nerve conduction studies in RFC1 + patients




























































































Length-dependent neuropathy = 13 (30%)
Absent LL SAPs/Reduced UL SAPs = 5 LL SAPs 5 UL SAPs = 8
Non length-dependent neuropathy = 30 (70%)
Absent SAPs at four limbs = 11 Absent UL SAPs/
Reduced LL SAPs = 5
UL SAPs 5 LL SAPs = 9 Globally absent SAPs with at least one SAP preserved = 5
Values are expressed as median (range) or n (%). CMAPs = compound muscle action potentials; LL = lower limbs; MCV = motor conduction velocity; SAPs = sensory action
potentials; SCV = sensory conduction velocity; Sup. Peroneal = superficial peroneal; UL = upper limbs.
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of vestibular symptoms, presence and distribution of
sensory symptoms and signs (other than proximal
reduction of vibratory sensation in the lower limbs),
presence of gait and limb ataxia.
Discussion
We identified RFC1 AAGGG biallelic expansions in 34% of
patients with sensory CIAP suggesting that RFC1
expansions represent a significant genetic cause of sporadic
sensory neuropathy.12,17
Frequency of RFC1 expansion in the
general peripheral nerve clinic
The AAGGG allele frequency in the general population is
0.7–6.8%,14,15,18 resulting in an estimated prevalence at
birth of biallelic carriers at risk of developing the disease
ranging from 1 in ’20 000 to 1 in ’200 individuals.
However, full CANVAS is considered relatively rare, while
idiopathic sensory neuropathy is common in the ageing
population.
We have previously hypothesized that sensory neurons
could be the first system to be involved in a context of pro-
gressive disease leading to full CANVAS.16 This was based
on the findings from a retrospective cohort of patients
Figure 4 Distribution of system involvement in RFC1 patients after clinical examination and investigations. Patients with isolated
sensory neuropathy were further subdivided depending on the presence of cough; patients with complex neuropathy who did not have the full
triad of CANVAS were further classified depending on the presence of vestibular or cerebellar dysfunction.
Table 3 Comparison of main clinical features and inves-
tigation results in RFC1-positive and -negative patients
RFC1 + RFC1– P-value
Mean age at onset 56 (30–75) 58 (12–85) 0.17
Male sex 25/43 (58%) 38/60 (63%) 0.59
Cough 26/37 (70%) 5/54 (9%) 0.00
Unsteadiness 30/43 (70%) 29/55 (53%) 0.08
History of falls 15/43 (35%) 6/56 (10%) 0.00
Chronic progression 35/43 (81%) 29/58 (50%) 0.00
Need for walking support 16/43 (37%) 6/58 (10%) 0.00
Sensory symptoms (non-length-
dependent distribution)
9/29 (31%) 13/47 (28%) 0.95
Impaired vibratory sensation at
knee or above
27/43 (63%) 13/57 (22%) 0.00
Non length-dependent pattern
at NCS
30/43 (70%) 15/55 (27%) 0.00
Absent SAPs at UL 22/35 (63%) 10/40 (25%) 0.00
Cerebellar symptoms 10/43 (23%) 4/56 (7%) 0.02
Cerebellar signs 20/40 (50%) 12/58 (21%) 0.00
Vestibular symptoms 4/43 (9%) 1/58 (1%) 0.09
Vestibular signs 12/26 (46%) 2/37 (5%) 0.00
Values are provided mean (range) or n (%). Values in bold indicate significance. NCS =
nerve conduction studies; SAPs = sensory action potentials; UL= upper limbs.
Figure 5 The ‘iceberg’ hypothesis for RFC1 spectrum dis-
orders. Complex neuropathy was defined by the contemporary
presence of neuropathy and vestibular or cerebellar involvement.
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affected by late-onset ataxia, including familial cases,
enrolled from highly specialized centres and with a specific
expertise in neurogenetics and inherited neuropathies.14,16
Overall, the frequency of carriers of biallelic RFC1 AAGGG
expansions in that series was 22%. The frequency in sporad-
ic sensory neuropathy has not yet been investigated.
In the present study, most of the cases were recruited from
general peripheral nerve and electromyography clinics, with-
out a bias towards genetic cases. Also, inclusion criteria
were limited to the presence of sensory neuropathy and not
of cerebellar ataxia or CANVAS. The study showed that in
this population the frequency of RFC1 expansion was as
high as 34%, significantly higher than the frequency
reported in previous ataxic cohorts, ranging from 2 to
22%.14,18–21 Thus, sensory nerve degeneration seems to play
a major and early role in RFC1-related ataxic disorders.
Although larger prospective studies are needed to elucidate
the full spectrum and the natural history of RFC1 spectrum
disorders, data from our cohort support an ‘iceberg’ hypoth-
esis, where full CANVAS represents the tip, whereas isolated
sensory neuropathy the bulk of the iceberg (Fig. 5).
Clinical features and diagnostic
clues of the RFC1 disease spectrum
RFC1-positive cases typically reported complaints suggestive
of distal symmetrical neuropathy including distal sensory
loss, paraesthesia, pain. Interestingly, a clinical-neurophysio-
logical dissociation between relatively mild clinical symp-
toms and signs, often in a length-dependent distribution, and
a more severe and widespread alteration of sensory action
potentials seems typical for RFC1 sensory neuropathy and
should prompt genetic testing.
Cerebellar symptoms were less common and oscillopsia
rare. Although ataxia is a key component of the disease and
the leading cause of disability during progression, unsteadi-
ness was reported by less than half of cases at onset and
observed in one-third at examination, while complaints of
upper limb incoordination were rare (510% of cases).
After clinical examination and investigation, the disease
was confirmed as an isolated sensory neuropathy in 42% of
RFC1 cases after a median of 9.6 years of disease duration.
Conversely, 58% had a complex neuropathy or CANVAS,
usually based on the presence of subtle clinical signs, includ-
ing nystagmus, broken pursuits and abnormal bedside head
impulse test, which can be missed if not specifically looked
for. The shorter disease duration in the present cohort com-
pared to our previously published CANVAS cohort (9.6
years, range 0–31 years versus 20 years, range 0–50 years)16
may explain the lower percentage of complex disease and
CANVAS and the lower degree of disability of our patients.
Interestingly, clinical examination seemed more accurate
than brain MRI in detecting cerebellar involvement. Indeed,
less than one-third of patients with signs of cerebellar dys-
function on examination had evidence of definite cerebellar
atrophy on brain MRI, while vestibular testing was mostly
confirmatory of abnormal bedside test. This is in accordance
with previous studies, showing that investigations seldom
show cerebellar atrophy and vestibular areflexia in patients
with a normal neurological examination.16,22
RFC1 sensory neuropathy
The study also helped to better define the sensory neur-
opathy in carriers of biallelic AAGGG expansions in RFC1,
including: (i) a length dependent distribution of sensory
symptoms and signs in 69% and 92% of cases, respectively,
mimicking a distal symmetrical polyneuropathy; (ii) the re-
port of loss of sensation and positive sensory symptoms
(which are unusual in genetic neuropathies) as the most
common complaint at disease onset, and more frequent than
unsteadiness; (iii) a preferential involvement of pinprick and
vibration sense with relative sparing of position sense; (iv)
variable reflexes, from absent to brisk (in accordance with
previous studies showing a preservation of H and T-reflexes,
as a result of the sparing of 1A muscle spindle afferent
fibres)23,24; (v) a frequent clinical-neurophysiological dissoci-
ation between the length-dependent distribution of sensory
symptoms and signs and the widespread impairment of sen-
sory conduction; and (vi) the confirmation that the motor
system is typically unaffected in RFC1 disorder, as RFC1
expansions were absent from 100 cases with sensory motor
neuropathy and RFC1-positive patients showed no or min-
imal motor involvement.
Chronic cough
The study also shows that a chronic cough is a strong diag-
nostic clue to suspect RFC1 expansion in patients with a
sensory neuropathy. Cough has been previously reported in
patients affected by cerebellar ataxia25 and hereditary sen-
sory neuropathy type 1B,26 but its origin remains unknown.
In RFC1 disease, cough often appears years or decades be-
fore the onset of sensory disturbances. Importantly, patients
seldom spontaneously report cough as a symptom and need
to be directly questioned about it. A history of asthma or
gastroesophageal reflux should not cause this symptom to
be dismissed in the context of a patient with sensory
neuropathy.
Misdiagnoses of RFC1 neuropathy
Positive RFC1 testing led to reclassification of 11 cases who
had a previous alternative diagnosis, including sensory
CIDP, Sjögren’s syndrome, paraneoplastic and metabolic
neuropathy, and entailing three cases who had received un-
necessary immune treatments. Therefore, it is of the utmost
importance to consider RFC1 in these cases to better inform
patients on their condition and prognosis, to offer genetic
counselling to patients and their families and to prevent
therapeutic attempts with ineffective and possibly detrimen-
tal drugs.
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Conclusion
After the exclusion of the common acquired causes, RFC1
should be considered in the diagnostic algorithm of all
patients with sporadic sensory, but not sensory-motor, CIAP
assessed in a general peripheral nerve clinic. Early diagnosis
of patients carrying biallelic RFC1 expansions, when the
sensory neuropathy is still isolated, is crucial both for ensur-
ing optimal patient management and for tracking the full
natural history of the disease, including its early stages,
when the neurodegenerative processes will likely be more
amenable to therapeutic interventions.27
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